Adagio Medical Holdings reported Q3 2026 net income of $17.8 million, driven by a $23.0 million noncash gain on convertible notes, while facing a diluted loss of $(5.13) per share. The company, which holds $3.1 million in cash, has initiated a formal process to explore strategic alternatives and recently completed a 1-for-30 reverse stock split to regain Nasdaq compliance.
Q3 net income of $17.8 million ($2.40 basic EPS) is entirely driven by a $23.0 million noncash fair-value gain on its 13% Convertible Notes, masking a diluted loss of $(5.13) per share. Cash of only $3.1 million, a pause in European commercial activity, a 1-for-30 reverse split to regain Nasdaq bid-price compliance, and a Board-initiated strategic alternatives review point to financial strain, but the strategic review could unlock value for shareholders. Good and bad largely cancel out.
- • Board-initiated formal process to explore strategic alternatives to maximize shareholder value
- • PMA application for the vCLAS Ventricular Ablation System still under FDA review
- • Cash and cash equivalents of only $3.1 million as of September 30, 2026
- • Commercial activity in Europe paused, with zero revenue in the quarter